Part 2. Imatinib for Gastrointestinal Stromal Tumors
(GISTs) (continued)
References
1. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal
stromal tumours. British Journal of Surgery Oct 2003;90(10):1178-1186.
2. DeMatteo RP, Lewis JJ, Leung D, et al. Two
hundred gastrointestinal stromal tumors: recurrence patterns and prognostic
factors for survival. Annals of Surgery Jan 2000;231(1):51-58.
3. Demetri GD, DeMatteo RP. NCCN Gastrointestinal
Stromal Tumors (GIST) Task Force Report: National Comprehensive Cancer Network;
2004.
4. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal
stromal tumors. Current Treatment Options in Oncology Dec 2001;2(6):485-491.
5. Conlon KC, Casper ES, Brennan MF. Primary
gastrointestinal sarcomas: analysis of prognostic variables. Annals of Surgical Oncology Jan 1995;2(1):26-31.
6. van Oosterom AT, Judson I, Verweij J, et
al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal
stromal tumours: a phase I study [see comment]. Lancet Oct 27 2001;358(9291):1421-1423.
7. Langer C, Gunawan B, Schuler P, et al. Prognostic
factors influencing surgical management and outcome of gastrointestinal stromal
tumours. British Journal of Surgery Mar 2003;90(3):332-339.
8. Lin SC, Huang MJ, Zeng CY, et al. Clinical
manifestations and prognostic factors in patients with gastrointestinal stromal
tumors. World Journal of Gastroenterology Dec 2003;9(12):2809-2812.
9. Graadt van Roggen JF, van Velthuysen ML,
Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal
stromal tumours. Journal of Clinical Pathology Feb 2001;54(2):96-102.
10. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal
stromal tumors: recent advances in understanding of their biology. Human Pathology Oct 1999;30(10):1213-1220.
11. Sarlomo-Rikala M, Kovatich AJ, Barusevicius
A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors
that is more specific than CD34. Modern Pathology Aug 1998;11(8):728-734.
12. Taniguchi M, Nishida T, Hirota S, et al. Effect
of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Research Sep 1 1999;59(17):4297-4300.
13. Lee JH, Zhang X, Jung WY, et al. DNA ploidy
and c-Kit mutation in gastrointestinal stromal tumors. World Journal of Gastroenterology
Dec 1 2004;10(23):3475-3479.
14. Yamaguchi M, Tate G, Endo Y, et al. Immunohistochemistry
and c-kit gene analysis in determining malignancy in gastrointestinal stromal
tumors. Hepato-Gastroenterology Sep-Oct 2003;50(53):1431-1435.
15. Miettinen M, Sobin LH, Lasota J. Gastrointestinal
stromal tumors of the stomach: a clinicopathologic, immunohistochemical,
and molecular genetic study of 1765 cases with long-term follow-up. American Journal of Surgical Pathology Jan 2005;29(1):52-68.
16. Wilson J, Connock M, Song F, et al. Imatinib
for the treatment of patients with unresectable and/or metastatic gastro-intestinal
stromal tumours—a systematic review and economic evaluation. Birmingham,
UK: National Institute for Clinical Excellence; October 10, 2003.
17. Ernst SI, Hubbs AE, Przygodzki RM, et al.
KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle
tumors. Laboratory Investigation Dec 1998;78(12):1633-1636.
18. Yasuoka R, Sakakura C, Shimomura K, et al.
Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic
tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation
as a prognostic biomarker for gastrointestinal mesenchymal tumor. Digestive Surgery 2003;20(3):183-191.
19. Morey AL, Wanigesekera GD, Hawkins NJ, et
al. C-kit mutations in gastrointestinal stromal tumours. Pathology Aug 2002;34(4):315-319.
20. Antonescu CR, Sommer G, Sarran L, et al. Association
of KIT exon 9 mutations with nongastric primary site and aggressive behavior:
KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal
tumors. Clinical Cancer Research Aug 15 2003;9(9):3329-3337.
21. Lasota J, Kopczynski J, Sarlomo-Rikala M,
et al. KIT 1530ins6 mutation defines a subset of predominantly malignant
gastrointestinal stromal tumors of intestinal origin. Human Pathology Dec
2003;34(12):1306-1312.
22. Yamamoto H, Oda Y, Kawaguchi K, et al. c-kit
and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal
stromal tumor of the soft tissue). American Journal of Surgical Pathology
Apr 2004;28(4):479-488.
23. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function
mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal
stromal tumors. Gastroenterology Sep 2003;125(3):660-667.
24. Miettinen M, El-Rifai W, Sobin, LH, et al.
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors:
a review. Human Pathology May 2002;33(5):478-483.
25. Fletcher CDM, Berman JJ, Corless C, , et al.
Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 2002;33(5):459-465.
26. Tryggvason G, Gíslason HG, Magnusson MK, et
al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic
GIST study, a population-based incidence and pathologic risk stratification
study. International Journal of Cancer 2005;117:289-293.
27. Heinrich MC, Shoemaker JS, Corless CL, et
al. Correlation of target kinase genotype with clinical activity of imatinib
mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing
KIT (KIT+). 2005 ASCO Annual Meetings, 2005: Abstract #7.
28. Anonymous. Adjuvant chemotherapy for localised
resectable soft-tissue sarcoma of adults: meta-analysis of individual data.
Sarcoma Meta-analysis Collaboration. Lancet Dec 6 1997;350(9092):1647-1654.
29. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide
in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):80-84.
30. Adult Soft Tissue Sarcoma (PDQ®): Treatment: Recurrent
Adult Soft Tissue Sarcoma. 2/1/05; http://cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page8#Reference8.12.
Accessed March 27, 2005.
31. Demetri GD, Elias AD. Results of single-agent
and combination chemotherapy for advanced soft tissue sarcomas. Implications
for decision making in the clinic. Hematology-Oncology Clinics of North America Aug 1995;9(4):765-785.
32. Bramwell V, Anderson D, Charette M. Doxorubicin-based
chemotherapy for the palliative treatment of adult patients with locally
advanced or metastatic soft tissue sarcoma. Practice Guideline Report #11-1.
July 2004; http://www.cancercare.on.ca/pdf/pebc11-1f.pdf. Accessed March
27, 2005.
33. Biermann JS, Baker LH. The future of sarcoma
treatment. Seminars in Oncology Oct 1997;24(5):592-597.
34. Antman KH, Ryan L, Elias A, et al. Response
to ifosfamide and mesna: 124 previously treated patients with metastatic
or unresectable sarcoma. Journal of Clinical Oncology Jan 1989;7(1):126-131.
35. van Oosterom AT, Mouridsen HT, Nielsen OS,
et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma
Group (STBSG) with two different ifosfamide regimens in first- and second-line
chemotherapy in advanced soft tissue sarcoma patients. European Journal of Cancer Dec 2002;38(18):2397-2406.
36. Patel SR, Vadhan-Raj S, Papadopolous N, et
al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase
II and pilot studies―dose-response and schedule dependence. Journal of Clinical Oncology Jun 1997;15(6):2378-2384.
37. Antman K, Crowley J, Balcerzak SP, et al.
An intergroup phase III randomized study of doxorubicin and dacarbazine with
or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Journal of Clinical Oncology Jul 1993;11(7):1276-1285.
38. Blanke CD, Corless CL. State-of-the Art Therapy
for Gastrointestinal Stromal Tumors. Cancer Investigation 2005;23(3):278-280.
39. von Mehren MWJC. Gastrointestinal stromal
tumors. Hematology-Oncology Clinics of North America 2005;19(3):547-564,
vii.
40. Eisenberg BL. Imatinib mesylate: a molecularly
targeted therapy for gastrointestinal stromal tumors. Oncology (Huntington)
1626 passim, 2003 Nov 1623;17(11):1615-1620; discussion 1620.
41. Corless CL, Schroeder A, Griffith D, et al.
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum
and in vitro sensitivity to imatinib. Journal of Clinical Oncology 2005;23(23):5357-5364.
42. Gleevec® and GIST. 2005; http://www.gleevec.com/info/page/gist. Accessed March 27, 2005.
43. Dagher R, Cohen M, Williams G, et al. Approval
summary: imatinib mesylate in the treatment of metastatic and/or unresectable
malignant gastrointestinal stromal tumors. Clinical Cancer Research Oct 2002;8(10):3034-3038.
44. Demetri GD, von Mehren M, Blanke CD, et al.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal
tumors. New England Journal of Medicine 2002;347(7):472-480.
45. van Oosterom AT, Judson IR, Verweij J, et
al. Update of phase I study of imatinib (STI571) in advanced soft tissue
sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft
Tissue and Bone Sarcoma Group. European Journal of Cancer Sep 2002;38 Suppl
5:S83-87.
46. Demetri GD, von Mehren M, Blanke CD, et al.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal
tumors [see comment]. New England Journal of Medicine Aug 15 2002;347(7):472-480.
47. Heinrich MC, Corless CL, Demetri GD, et al.
Kinase mutations and imatinib response in patients with metastatic gastrointestinal
stromal tumor. Journal of Clinical Oncology Dec 1 2003;21(23):4342-4349.
48. Verweij J, van Oosterom A, Blay JY, et al.
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal
stromal tumours, but does not yield responses in other soft-tissue sarcomas
that are unselected for a molecular target. Results from an EORTC Soft Tissue
and Bone Sarcoma Group phase II study [see comment]. European Journal of Cancer Sep 2003;39(14):2006-2011.
49. Verweij J, Casali PG, Zalcberg J, et al. Progression-free
survival in gastrointestinal stromal tumours with high-dose imatinib: randomised
trial [see comment]. Lancet Sep 25 2004;364(9440):1127-1134.
50. Zalcberg J, Verweij J, Casali PG, et al. Outcome
of patients with advanced gastro-intestinal stromal tumors (GIST) crossing
over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD)―an
international, intergroup study of the EORTC, ISG and AGITG. Journal of Clinical Oncology 2004;22(14S):9004.
51. Casali P, Fumagalli E, Messina A, et al. Tumor
response to imatinib mesylate in advanced GIST. Journal of Clinical Oncology
2004;22(14S):9028.
52. Blay J-Y, Berthaud P, Perol D, et al. Continuous
vs intermittent imatinib treatment in advanced GIST after one year: a prospective
randomized phase III trial of the French Sarcoma Group. Journal of Clinical Oncology 2004;22(14S):9006.
53. Rankin C, von Mehren M, Blanke C, et al. Dose
effect of imatinib (IM) in patients (pts) with metastatic GIST—Phase III
Sarcoma Group Study S0033. Journal of Clinical Oncology 2004;22(14S):9005.
54. Patel SR. Early results from randomized phase
III trial of imatinib mesylate for gastrointestinal stromal tumors. Current Oncology Reports Jul 2003;5(4):273.
55. Bumming P, Andersson J, Meis-Kindblom JM,
et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal
stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
British Journal of Cancer Aug 4 2003;89(3):460-464.
56. Rutkowski P, Nyckowski P, Grzesiakowska U,
et al. The clinical characteristics and the role of surgery and imatinib
treatment in patients with liver metastases from c-Kit positive gastrointestinal
stromal tumors (GIST). Neoplasma 2003;50(6):438-442.
57. Scaife CL, Hunt KK, Patel SR, et al. Is there
a role for surgery in patients with "unresectable" cKIT+ gastrointestinal
stromal tumors treated with imatinib mesylate? American Journal of Surgery
Dec 2003;186(6):665-669.
58. Wu PC, Langerman A, Ryan CW, et al. Surgical
treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Surgery Oct 2003;134(4):656-665; discussion 665-656.
59. Debiec-Rychter M, Dumez H, Judson I, et al.
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response
to imatinib in patients with advanced gastrointestinal stromal tumours entered
on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
European Journal of Cancer Mar 2004;40(5):689-695.
60. Frolov A, Chahwan S, Ochs M, et al. Response
markers and the molecular mechanisms of action of Gleevec in gastrointestinal
stromal tumors. Molecular Cancer Therapeutics Aug 2003;2(8):699-709.
61. Stroobants S, Goeminne J, Seegers M, et al.
18FDG-Positron emission tomography for the early prediction of response in
advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) [see
comment]. European Journal of Cancer Sep 2003;39(14):2012-2020.
62. Antoch G, Kanja J, Bauer S, et al. Comparison
of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571)
therapy in patients with gastrointestinal stromal tumors. Journal of Nuclear Medicine Mar 2004;45(3):357-365.
63. Gayed I, Vu T, Iyer R, et al. The role of
18F-FDG PET in staging and early prediction of response to therapy of recurrent
gastrointestinal stromal tumors [erratum appears in J Nucl Med 2004 Nov;45(11):1803].
Journal of Nuclear Medicine Jan 2004;45(1):17-21.
64. De Giorgi U, Aliberti G, Benea G, et al. Effect
of angio-echography with a second-generation contrast agent to assess tumor
response to imatinib treatment in patients with advanced gastrointestinal
stromal tumor (GIST): Comparison with computerized tomography (CT). Journal of Clinical Oncology 2004;22(14S):4216.
65. Lassau N, Lamuraglia M, Leclere J, et al.
Doppler-Ultrasonography with perfusion software and contrast medium injection
as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated
by imatinib: Results of a prospective study. Journal of Clinical Oncology
2004;22(14S):9048.
66. Hellies R, Sulis R, Puliga A, et al. [GIST:
surgical treatment of 34 cases]. Tumori Jul-Aug 2003;89(4 Suppl):133-134.
67. Michael M, Tannock IF. Measuring health-related
quality of life in clinical trials that evaluate the role of chemotherapy
in cancer treatment. Canadian Medical Association Journal 1998;158(13):1727-1734.
68. Dematteo RD, Heinrich MC, El-Rifai WM, et
al. Clinical management of gastrointestinal stromal tumors: before and after
STI-571. Human Pathology 2002;33(5):466-477.
69. Demetri G, von Mehren, M, Joensuu, H, et
al. Lack of progress is the most significant measure of patients's lack of
clinical benefit: correlating the effects of imatinib meslyate therapy in
gastrointestinal stromal tumor (GIST) with survival benefits. Annals of Oncology
2004;15(s3):iii202.
70. ClinPharm Online. http://cpip.gsm.com,
2005.
71. Verweij J, Casali PB, Zalcberg J, et al. Progression-free
survival in gastrointestinal stromal tumours with high-dose imatinib: randomised
trial. Lancet 2004;364:1127-1134.
72. Zalcberg JR, Verweij J, Casali PG, et al.
Outcome of patients with advanced gastro-intestinal stromal tumors (GIST)
crossing over to a daily imatinib dose of 800mg (HD) after progression on
400mg (LD)—an international, intergroup study of the EORTC, ISG and AGITG.
Journal of Clinical Oncology 2004;22(14):9004.
73. Rankin C, Von Mehren M, Blanke C, et al. Dose
effect of imatinib (IM) in patients (pts) with metastatic GIST—Phase III
Sarcoma Group Study S0033. Journal of Clinical Oncology. 2004;22(14):9005.
74. D'Amato G, Steinert DM, McAuliffe JC, et al.
Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12(1):44-56.
75. Milandri C, Passardi A, Dall'agata M, et al.
Gastrointestinal stromal tumors and breast cancer: any correlation? Report
of two clinical cases. Journal of Clinical Oncology 2005;23(16S):abstract
#9049.
76. Linton KM, Taylor MB, Radford JA. Response
evaluation in GIST treated with imatinib-misdiagnosis of disease progression
on CT due to cystic change in liver metastases. Journal of Clinical Oncology
2005;23(16S):abstract #9047.
77. Khan A. Efficacy of imatinib mesylate in metastatic
GIST to the brain. Journal of Clinical Oncology 2005;23(16S):abstract #9050.
78. Leong KW, Goh SA. Observation study on Asian
patients taking Imatinib mesylate in comparison to published data focusing
on dosage and adverse events. Journal of Clinical Oncology 2005;23(16S):abstract
#6727.
79. Gronchi A, Fiore M, Bertulli R, et al. Surgery
of residual disease following Imatinib mesylate in advanced gastrointestinal
stromal tumors (GIST). Journal of Clinical Oncology 2005;23(16S):abstract
#9038.
80. Rutkowski P, Nowecki Z, Nyckowski P, et al.
Surgical treatment of patients (pts) with gastrointestinal stromal tumors
(GIST) after imatinib mesylate (IM) therapy. Journal of Clinical Oncology
2005;23(16S):abstract 9037.
81. Trent JC, Choi H, Hunt K, et al. Apoptotic
and anti-vascular activity of imatinib in GIST patients. Journal of Clinical Oncology 2005;23(16S):abstract #9001.
82. Lassau N, Lamuraglia M, Chami L, et al. Doppler-Ultrasonography
with perfusion software and contrast medium injection as a tool for early
evaluation of gastro-intestinal stromal tumors (GIST) treated with Imatinib.
Journal of Clinical Oncology 2005;23(16S):abstract #3057.
83. Blackstein Me, Rankin CJ, Fletcher C, et al.
Clinical benefit of Imatinib in patients (pts) with metastatic Gastrointestinal
Stromal Tumors (GIST) negative for the expression of CD117 in the S0033 trial.
Journal of Clinical Oncology 2005;23(16S):abstract #9010.
84. Dileo P, Rankin CJ, Bejamin RS, et al. Incidence
and reasons for dose modification of standard-dose vs. high-dose Imatinib
Mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with
unresectable or metastatic Gastrointestinal Stromal Tumor (GIST). Journal of Clinical Oncology 2005;23(16S):abstract #9032.
85. Heinrich M, Shoemaker JS, Corless CL, et al.
Correlation of target kinase genotype with clinical activity of imatinib
mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing
KIT (KIT+). Journal of Clinical Oncology 2005;23(16S):abstract #7.
86. Ray-Coquard I, Perol D, Bui BN, et al. Prognostic
factors for progression free and overall survival in advanced GIST: results
from the BFR14 phase III trial of the French Sarcoma Group. Journal of Clinical Oncology 2005;23(16S):abstract #9035.
87. Le Cesne A, Perol D, Ray-Coquard I, et al.
Interruption of imatinib (IM) in GIST patients with advanced disease: updated
results of the prospective French Sarcoma Group randomized phase III trial
on survival and quality of life. Journal of Clinical Oncology 2005;23(16S):abstract
#9031.
88. Dematteo RP, Antonescu CR, Chadaram V, et
al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal
stromal tumor (GIST) following complete resection: Safety results from the
U.S. Intergroup Phase II trial ACOSOG Z9000. Journal of Clinical Oncology
2005;23(16S):Abstract #9009.
89. Bustamante F, Castillo E, Silva A, et al.
Experiences with gastrointestinal stromal tumour at the Oncology Hospital
Siglo XXI IMSS. Journal of Clinical Oncology 2005;23(16S):abstract #9048.
90. Stepanova E, Meshcheryakov A, Anurova O, et
al. Immunohistochemical markers as prognostic indicators for efficacy of
imatinib therapy in GIST. Journal of Clinical Oncology 2005;23(16S):abstract
#9703.
91. Ryu M, Lee H, Kim T, et al. p53 mutation as
a determinant of prognosis in GIST patients treated with Imatinib mesylate.
Journal of Clinical Oncology 2005;23(16S):abstract #9018.
92. Kim J, Lim M, Kim I, et al. Prognostic analysis
of gastrointestinal stromal tumor by mitotic activity, size of tumor and
mutational type of C-Kit protein. Journal of Clinical Oncology 2005;23(16S):abstract #9046.
93. Aliberti S, Grignani G, Allione P, et al.
Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained
finding in GIST imatinib (I) chronic therapy. Journal of Clinical Oncology
2005;23(16S):abstract #9045.
94. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in Western Sweden. Cancer 2005;103(4)821-9.
Return to Contents
Proceed to Next Section